Actively Recruiting
Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
Led by University of Toronto · Updated on 2025-10-02
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
U
University of Toronto
Lead Sponsor
D
Diabetes Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.
CONDITIONS
Official Title
Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged >18 years
- Body mass index >30 kg/m2 and <50 kg/m2
- Have access to an Apple or Android cellphone with Bluetooth
- Have type 2 diabetes or be at risk for type 2 diabetes (defined as high (33+) Canadian Diabetes Risk Score)
You will not qualify if you...
- For individuals with type 2 diabetes: currently on >3 diabetes medications
- For individuals with type 2 diabetes: diabetes medication dosage changed within the last 3 months
- For individuals with type 2 diabetes: self-reported hemoglobin A1c >9.0%
- For individuals with type 2 diabetes: taking exogenous insulin
- For individuals with type 2 diabetes: taking sulfonylureas
- History of or referral for bariatric surgery
- Weight loss >5% in the last 3 months
- Taking antiobesity (weight loss) medications
- Body weight >340 lbs
- Diagnosed cognitive disorder preventing informed consent
- Unable or unwilling to change eating window as prescribed
- Currently eating during a <12 hour period on 5 or more days per week
- Physician-diagnosed eating disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Remote Ontario-wide
Toronto, Ontario, Canada
Actively Recruiting
Research Team
A
Amy A Kirkham, PhD
CONTACT
R
Rebecca AG Christensen, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here